drugset
drugset / Trial / NCT02112526

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

NCT02112526 ↗

Phase 1 Completed 21 enrolled Acerta Pharma BV
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To characterize the safety profile of acalabrutinib in subjects with relapsed or refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL).

Timeline

Start
2014-08-07
Primary completion
2020-06-30
Completion
2024-10-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Acalabrutinib Small molecule — —

Indications

diffuse large B-cell lymphoma activated B-cell type